News from NORD

Alport Syndrome Research Funding Is Awarded


 

Researchers at the University of Miami in Florida and University of Cyprus have each been awarded $100,000 to explore two drug repurposing projects to identify possible treatments for Alport syndrome. The funding was provided by the Alport Syndrome Foundation, Pedersen Family, and the Kidney Foundation of Canada.

Alport syndrome is a genetic condition characterized by kidney disease, hearing loss and eye abnormalities. When the Alport Syndrome Foundation was established in 2007, there was little funding or interest in researching this rare condition. In recent years, partly as a result of the foundation’s support for research and development of basic resources to assist researchers, several potential new treatments have entered the pipeline and are in development. Read more about this and the recent funding awards on the foundation’s website .

Recommended Reading

New genetic causes of ichthyoses likely to emerge
MDedge Dermatology
Amyopathic Dermatomyositis With Plantar Keratoderma Responding to Methotrexate Therapy
MDedge Dermatology
Developing vaccines against enterovirus-A71 called a priority
MDedge Dermatology
FDA grants breakthrough status to epidermolysis bullosa gene therapy
MDedge Dermatology
Presumed Serum Sickness Following Thymoglobulin Treatment of Acute Cellular Rejection of a Cardiac Allograft
MDedge Dermatology
Targeted therapy may be possible for pityriasis rubra pilaris
MDedge Dermatology
Immunologic testing is key to diagnosing autoimmune blistering diseases
MDedge Dermatology
Join the National Organization for Rare Disorders and the University of Massachusetts for Two Upcoming CME-Accredited Events
MDedge Dermatology
Rare Disease Film Festival Is Planned
MDedge Dermatology
NORD Outlines Recommendations for Health Care Reform in Letter to Congressional Leadership
MDedge Dermatology